No active 13F manager changed its position in Climb Bio, Inc. last quarter. Over the last 180 days, 1 insider sold and none bought, a net -$407K in open-market trades.
The legs disagree, or only one of them leans.
Not held in any tracked 13F filing yet.
Holders and values reflect the 13F filers Arkolith currently tracks, not the entire institutional universe. Counts and totals are a floor, not the full institutional ownership.
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| Jun 29, 2026 | Brennan Aoife | President and CEO, Director | Sell (S) | 31K | $407K |
| Feb 26, 2026 | Thomas Stephen Basil | Director | Sell (S) | 16K | $114K |
| Feb 25, 2026 | Thomas Stephen Basil | Director | Sell (S) | 34K | $236K |
| Feb 13, 2026 | Thomas Stephen Basil | Director | Sell (S) | 10K | $58K |
| Feb 12, 2026 | Thomas Stephen Basil | Director | Sell (S) | 90K | $471K |
| Jan 5, 2026 | RA Capital Healthcare Fund LP | Director, 10% Owner | Buy (P) | 7K | $25K |
| Dec 12, 2025 | Kolchinsky Peter | Director, 10% Owner | Buy (P) | 101K | $290K |
| Dec 11, 2025 | Kolchinsky Peter | Director, 10% Owner | Buy (P) | 213K | $465K |
| Jun 30, 2025 | Brennan Aoife | President and CEO, Director | Sell (S) | 21K | $25K |
| Jun 20, 2025 | Pimblett Emily | SVP, Finance & CAO | Sell (S) | 1K | $2K |
| Mar 20, 2025 | Pimblett Emily | SVP, Finance & CAO | Sell (S) | 1K | $2K |
| Dec 19, 2024 | Pimblett Emily | CHIEF ACCOUNTING OFFICER | Sell (S) | 1K | $2K |
Where institutional funds (13F), corporate insiders (Form 4) and US House members (STOCK Act) are buying or selling the same name in the same window. Green is buying, red is selling.
Insiders and Congress: last 180 days. Funds: latest 13F, top 100 holders incl. passive
| Source | Buying | Selling | Net |
|---|---|---|---|
13F funds Top 100 holders by value, passive included; the hero counts active managers only | 0 | 0 | – |
Insiders Form 4 open-market | 0 | 1 | -$407K |
US House STOCK Act trades | 0 | 0 | $0 |
Capital Rotation reports where institutional capital disclosed rotating, as of the latest public SEC 13F filings. It is data, not investment advice, a recommendation, or a prediction. Filings lag about 45 days and cover long US equity positions only. Past disclosed flows do not indicate future prices. Do your own research; consult a licensed advisor.
Connected entities for Climb Bio, Inc.
This stock page is the public Follow view. For one current, evidence-backed answer, use capital_change_brief through REST or MCP. It compares tracked 13F changes with qualifying Form 4 activity and cites the SEC evidence.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/stocks/ELYM/capital-change-brief"
Use Arkolith's capital_change_brief for Climb Bio, Inc.. Tell me what changed, whether insider activity corroborates it, and cite the SEC evidence.
13F holdings + Form 4 insider transactions + the live filing stream, joined for ELYM. Filings are public domain, sourced to SEC EDGAR.